GTBP News and Press, GT Biopharma Inc. From 03/30/23

Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January 4, 2023. Cash on hand, coupled with significant recent cost redu...

2023-03-24 07:13:27 ET Summary Fate Therapeutics' recent Janssen debacle has brought out comparisons with Geron. However, let's not forget that Geron has never gone back to pre-2019 prices. Fate investors would do well when they rethink their strategy. Fate Therapeut...

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that Dr...

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...

Cancer-focused nano-cap biotech GT Biopharma ( NASDAQ: GTBP ) lost ~8% in the pre-market trading Friday after announcing a registered direct offering to sell 6.5M shares of its common stock and warrants to raise $6.5M in gross proceeds. The capital raise is part of an agreement th...

BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...

Clinical stage immuno-oncology company focused on developing innovative therapeutics, GT Biopharma ( NASDAQ: GTBP ) based on the company's proprietary natural killer (NK) cell engager, TriKE platform, has named Dr. Jeff Miller, renowned NK ell cancer specialist as consu...

BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...

Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announce...

Poster #1: Tri-specific killer engagers target natural killer cells towards mesothelioma Poster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) BRISB...